Similar Search Results

Narrow search

Prediction of Individual Long-term Outcomes in Smoking Cessation Trials Using Frailty Models

Li, Yimei; Wileyto, E. Paul; Heitjan, Daniel F. - In: Biometrics 67 (2011) 4, pp. 1321-1329

Persistent link: https://www.econbiz.de/10010947265

A Simple Local Sensitivity Analysis Tool for Nonignorable Coarsening: Application to Dependent Censoring

Zhang, Jiameng; Heitjan, Daniel F. - In: Biometrics 62 (2006) 4, pp. 1260-1268

Persistent link: https://www.econbiz.de/10010948017

Multiple Imputation for Model Checking: Completed-Data Plots with Missing and Latent Data

Gelman, Andrew; Mechelen, Iven Van; Verbeke, Geert; … - In: Biometrics 61 (2005) 1, pp. 74-85

Persistent link: https://www.econbiz.de/10010948423

Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis by DANIELS, M. J. and HOGAN, J. W.

Heitjan, Daniel F. - In: Biometrics 65 (2009) 1, pp. 328-328

Persistent link: https://www.econbiz.de/10010948438

Bayesian Analysis of a Protocol for Sampling Preserved Tumor Specimens

Heitjan, Daniel F. - In: Journal of the American Statistical Association : JASA 90 (1995) 429, pp. 38-44

Persistent link: https://www.econbiz.de/10006634779

Assessing Secular Trends in Blood Pressure: A Multiple-Imputation Approach

Heitjan, Daniel F.; Landis, J.Richard - In: Journal of the American Statistical Association : JASA 89 (1994) 427, pp. 750-759

Persistent link: https://www.econbiz.de/10006636574

Bayesian estimation of cost-effectiveness: an importance-sampling approach

Heitjan, Daniel F.; Li, Huiling - In: Health Economics 13 (2004) 2, pp. 191-198

We describe a method for estimating the cost-effectiveness of a new treatment compared to a standard, using data from a comparative clinical trial. We quantify the clinical effectiveness as a binary variable indicating success or failure. The underlying statistical model assumes that costs are...

Persistent link: https://www.econbiz.de/10005689856

Bayesian estimation of cost-effectiveness ratios from clinical trials

Heitjan, Daniel F.; Moskowitz, Alan J.; Whang, William - In: Health Economics 8 (1999) 3, pp. 191-201

Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean...

Persistent link: https://www.econbiz.de/10005694137